公开(公告)号：US20180079756A1

公开(公告)日：2018-03-22

申请号：US15563161

申请日：2016-03-29

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Shuhei IKEDA ,  Tatsuki KOIKE ,  Jumpei AIDA ,  Makoto FUSHIMI ,  Tomokazu KUSUMOTO ,  Hideyuki SUGIYAMA ,  Masako MIYAZAKI ,  Hidekazu TOKUHARA ,  Yasushi HATTORI ,  Makoto KAMATA

IPC: C07D498/04 ,  C07D401/10 ,  C07D413/10 ,  C07D413/14 ,  C07D417/14

CPC classification number: C07D498/04 ,  A61K31/454 ,  A61K31/4709 ,  A61K31/538 ,  A61K31/5383 ,  C07D401/06 ,  C07D401/10 ,  C07D413/06 ,  C07D413/10 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C12N9/99

Abstract: The present invention provides a compound having an MAGL inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like.The present invention relates a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.

公开(公告)号：US20170283406A1

公开(公告)日：2017-10-05

申请号：US15474192

申请日：2017-03-30

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Shuhei Ikeda ,  Hideyuki SUGIYAMA ,  Jumpei AIDA ,  Hidekazu TOKUHARA ,  Tomohiro OKAWA ,  Yuya OGURO ,  Minoru NAKAMURA ,  Masataka MURAKAMI

IPC: C07D413/14 ,  C07D413/08 ,  C07D405/14 ,  C07D401/08

CPC classification number: C07D413/14 ,  C07D401/06 ,  C07D401/08 ,  C07D405/14 ,  C07D413/06 ,  C07D413/08

Abstract: The present invention provides a compound having an MAGL inhibitory action, and useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like.The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

公开(公告)号：US20210363130A1

公开(公告)日：2021-11-25

申请号：US17042394

申请日：2019-03-28

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Koji ONO ,  Masahiro ITO ,  Toshio TANAKA ,  Moriteru ASANO ,  Takaharu HIRAYAMA ,  Jun FUJIMOTO ,  Nobuki SAKAUCHI ,  Yasuhiro HIRATA ,  Akinori TOITA ,  Nao MORISHITA ,  Hironori KOKUBO ,  Yasuhiro IMAEDA ,  Hironobu MAEZAKI ,  Douglas Robert CARY ,  Ryo MIZOJIRI ,  Nobuo CHO ,  Hiroshi BANNO ,  Hidekazu TOKUHARA ,  Yasuyoshi ARIKAWA

IPC: C07D401/14 ,  A61P35/00 ,  C07D401/12 ,  C07D405/14 ,  C07D405/12 ,  C07D213/84 ,  C07D403/14 ,  C07D403/12 ,  C07D471/10 ,  C07D487/10 ,  C07D495/10

Abstract: Provided is a compound that may have a superior CDK12 inhibitory action and is expected to be useful as a prophylactic or therapeutic drug for cancer and the like. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

公开(公告)号：US20190125728A1

公开(公告)日：2019-05-02

申请号：US16089548

申请日：2017-03-30

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Shuhei IKEDA ,  Hideyuki SUGIYAMA ,  Jumpei AIDA ,  Hidekazu TOKUHARA ,  Tomohiro OKAWA ,  Yuya OGURO ,  Minoru NAKAMURA ,  Masataka MURAKAMI

IPC: A61K31/4188 ,  A61K31/407 ,  A61K31/454 ,  A61K31/496 ,  A61P25/16 ,  A61P25/08 ,  A61P25/24 ,  A61P25/28 ,  A61P21/00

Abstract: The present invention provides a compound having an MAGL inhibitory action, and useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like.The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

公开(公告)号：US20160176872A1

公开(公告)日：2016-06-23

申请号：US15055108

申请日：2016-02-26

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Satoshi YAMAMOTO ,  Junya SHIRAI ,  Tsuneo ODA ,  Mitsunori KONO ,  Atsuko OCHIDA ,  Takashi IMADA ,  Hidekazu TOKUHARA ,  Yoshihide TOMATA ,  Naoki ISHII ,  Michiko TAWADA ,  Yoshiyuki FUKASE ,  Tomoya YUKAWA ,  Shoji FUKUMOTO

IPC: C07D471/04

CPC classification number: C07D217/26 ,  A61K31/4375 ,  A61K31/472 ,  A61K31/4741 ,  C07D217/14 ,  C07D471/04 ,  C07D491/048 ,  C07D491/056 ,  C07D491/14 ,  C07F7/0812

Abstract: The present invention provides a heterocyclic compound having a RORγt inhibitory action.The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification. or a salt thereof.

Abstract translation: 本发明提供具有RORγt抑制作用的杂环化合物。 本发明涉及由式（I）表示的化合物：其中每个符号如说明书中所定义。 或其盐。

公开(公告)号：US20230117295A1

公开(公告)日：2023-04-20

申请号：US18075853

申请日：2022-12-06

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Koji ONO ,  Masahiro ITO ,  Toshio TANAKA ,  Moriteru ASANO ,  Takaharu HIRAYAMA ,  Jun FUJIMOTO ,  Nobuki SAKAUCHI ,  Yasuhiro HIRATA ,  Akinori TOITA ,  Nao MORISHITA ,  Hironori KOKUBO ,  Yasuhiro IMAEDA ,  Hironobu MAEZAKI ,  Douglas Robert CARY ,  Ryo MIZOJIRI ,  Nobuo CHO ,  Hiroshi BANNO ,  Hidekazu TOKUHARA ,  Yasuyoshi ARIKAWA

IPC: C07D401/14 ,  C07D403/14 ,  C07D401/12 ,  C07D471/10 ,  C07D495/10 ,  C07D405/12 ,  C07D403/12 ,  C07D213/84 ,  C07D487/10 ,  C07D405/14 ,  A61P35/00

Abstract: Provided is a compound that may have a superior CDK12 inhibitory action and is expected to be useful as a prophylactic or therapeutic drug for cancer and the like. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

公开(公告)号：US20200255439A1

公开(公告)日：2020-08-13

申请号：US16651840

申请日：2018-09-27

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Makoto KAMATA ,  Hideyuki SUGIYAMA ,  Minoru NAKAMURA ,  Masataka MURAKAMI ,  Shuhei IKEDA ,  Tomohiro OKAWA ,  Hidekazu TOKUHARA

IPC: C07D487/10 ,  A61P25/28 ,  A61K9/48 ,  A61K9/20

Abstract: The present invention provides a compound having an MAGL inhibitory action, and expected to be useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like.The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.

公开(公告)号：US20160002169A1

公开(公告)日：2016-01-07

申请号：US14755439

申请日：2015-06-30

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Satoshi YAMAMOTO ,  Junya SHIRAI ,  Tsuneo ODA ,  Mitsunori KONO ,  Atsuko OCHIDA ,  Takashi IMADA ,  Hidekazu TOKUHARA ,  Yoshihide TOMATA ,  Naoki ISHII ,  Michiko TAWADA ,  Yoshiyuki FUKASE ,  Tomoya YUKAWA ,  Shoji FUKUMOTO

IPC: C07D217/26 ,  C07D491/056 ,  C07D491/048 ,  C07F7/08 ,  C07D471/04

CPC classification number: C07D217/26 ,  A61K31/4375 ,  A61K31/472 ,  A61K31/4741 ,  C07D217/14 ,  C07D471/04 ,  C07D491/048 ,  C07D491/056 ,  C07D491/14 ,  C07F7/0812

Abstract: The present invention provides a heterocyclic compound having a RORγt inhibitory action.The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification. or a salt thereof.

公开(公告)号：US20160318864A1

公开(公告)日：2016-11-03

申请号：US15108000

申请日：2014-12-25

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Tatsuki KOIKE ,  Makoto FUSHIMI ,  Jumpei AIDA ,  Shuhei IKEDA ,  Tomokazu KUSUMOTO ,  Hideyuki SUGIYAMA ,  Hidekazu TOKUHARA

IPC: C07D207/273 ,  C07D403/12 ,  C07D409/12 ,  C07D401/12 ,  C07D403/14 ,  C07D417/14 ,  C07D413/12 ,  C07D471/04 ,  C07D401/14 ,  C07D417/12 ,  C07D405/12

CPC classification number: C07D207/273 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/12 ,  C07D403/14 ,  C07D405/12 ,  C07D409/12 ,  C07D413/12 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04

Abstract: The present invention aims to provide a compound having an MAGL inhibitory action, and useful as a prophylactic or therapeutic agent for neurodegenerative diseases (e.g., Alzheimer's disease, Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis and the like), anxiety disorder, pain (e.g., inflammatory pain, carcinomatous pain, nervous pain and the like), epilepsy and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

Abstract translation: 其中每个符号如说明书中所述或其盐。

公开(公告)号：US20160046601A1

公开(公告)日：2016-02-18

申请号：US14925259

申请日：2015-10-28

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Takanobu KUROITA ,  Yasuhiro IMAEDA ,  Kouichi IWANAGA ,  Naohiro TAYA ,  Hidekazu TOKUHARA ,  Yoshiyuki FUKASE

IPC: C07D401/12 ,  C07D495/04 ,  C07D413/14 ,  C07D401/14 ,  C07D453/02 ,  C07D471/04 ,  C07D405/14

CPC classification number: C07D401/12 ,  C07D233/90 ,  C07D401/14 ,  C07D405/14 ,  C07D407/12 ,  C07D409/06 ,  C07D409/14 ,  C07D413/06 ,  C07D413/14 ,  C07D417/06 ,  C07D417/12 ,  C07D453/02 ,  C07D471/04 ,  C07D487/04 ,  C07D487/08 ,  C07D495/04

Abstract: Compounds represented by the formulas wherein each symbol is as defined in the specification, and a prodrug thereof have a superior renin inhibitory activity, and are useful as agents for the prophylaxis or treatment of hypertension, various organ damages attributable to hypertension and the like.